Boston Standard Wealth Management LLC Sells 591,469 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Boston Standard Wealth Management LLC decreased its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,165 shares of the company's stock after selling 591,469 shares during the quarter. Boston Standard Wealth Management LLC's holdings in Ginkgo Bioworks were worth $124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Wellington Wealth Strategies LLC. purchased a new position in shares of Ginkgo Bioworks during the 2nd quarter valued at $41,000. Algert Global LLC bought a new position in shares of Ginkgo Bioworks in the second quarter worth approximately $36,000. Mackenzie Financial Corp bought a new stake in Ginkgo Bioworks during the second quarter valued at approximately $251,000. AQR Capital Management LLC purchased a new position in Ginkgo Bioworks in the 2nd quarter worth approximately $3,391,000. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of Ginkgo Bioworks by 1,606.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company's stock worth $79,000 after buying an additional 221,078 shares during the last quarter. Hedge funds and other institutional investors own 78.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on DNA shares. TD Cowen boosted their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, September 20th. BTIG Research raised their target price on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a report on Friday, August 23rd. Finally, The Goldman Sachs Group decreased their target price on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a "sell" rating on the stock in a research note on Tuesday, July 9th. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $4.16.

Ginkgo Bioworks Stock Up 0.4 %

NYSE:DNA traded up $0.03 during trading hours on Monday, hitting $8.36. The company had a trading volume of 651,721 shares, compared to its average volume of 1,162,510. The stock has a market cap of $18.49 billion, a P/E ratio of -18.93 and a beta of 1.10. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $75.20.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($3.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($3.20). Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. The firm had revenue of $56.21 million for the quarter, compared to analyst estimates of $41.46 million. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 EPS for the current fiscal year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.